Massachusetts cannabis industry is drowning in debt, Missouri regulators are tightening microbusiness oversight, and eight states are pushing medical conscience laws that could let healthcare providers refuse cannabis treatment — marking a critical moment where cannabis policy is fracturing along economic, regulatory, and ideological lines.
In Massachusetts, the once-optimistic pot industry now faces a crisis of its own making. 💰 MONEY MOVES The state generated $289 million in cannabis taxes last year and employs 21,000 people, but oversaturation has cratered prices and left shops, cultivators, and associated companies unable to pay lenders, taxes, or suppliers. The average retail price for an ounce of flower dropped from over $400 in 2020 to $114.82 this January, after 113 million plants were harvested in December 2025 compared to just 10 million in late 2020. The problem isn't just market saturation — it's structural. Cannabis companies face higher federal taxes under Section 280E because federal law still treats them as illegal, lack access to traditional bank loans, pay "impact" fees other businesses don't, face municipal zoning restrictions that drive up rent, and navigate strict regulations that inflate operational costs. Lawmakers and regulators are debating whether government should intervene to stabilize the market, though some argue a free market should eventually rightsize itself.
Meanwhile, Missouri's social-equity cannabis program is getting a regulatory overhaul after years of documented abuse. The state's Joint Committee on Administrative Rules approved new microbusiness rules Thursday meant to prevent a repeat of what's already happened: of 105 microbusiness licenses issued since 2023, 35 have been revoked. Amy Moore, director of the Missouri Division of Cannabis Regulation, told lawmakers that well-connected groups and individuals have been flooding the lottery by recruiting eligible applicants and then offering contracts that strip them of profit and control. The new rules will move the division's ownership review to before licenses are issued rather than after — a shift designed to prevent another wave of revocations. However, lawmakers stripped out a proposed ban on people tied to denied or revoked licenses from holding interests in future microbusinesses, with Republican Rep. Ben Keathley arguing the language was too broad. The microbusiness program was specifically designed to boost opportunities for people in disadvantaged communities most impacted by the war on drugs.
But while states work to regulate cannabis commerce, eight states are moving in the opposite direction — expanding medical conscience laws that would let healthcare providers refuse to prescribe or provide medical marijuana, along with contraception, fertility services, and vaccines, on religious or moral grounds. Kentucky, Missouri, New Hampshire, Oklahoma, Rhode Island, South Carolina, Utah, and West Virginia have all introduced expanded medical conscience legislation this year, many backed by national anti-abortion groups like the Alliance Defending Freedom. Supporters say the measures protect providers from being sued or fired for following deeply held beliefs. Critics warn the language is so broad that it would let doctors, pharmacists, hospitals, and insurers refuse just about anything, undermining patients' right to comprehensive care. 🤔 THINK ABOUT IT A patient in Tennessee was already prepped for a sterilization procedure with an IV in her arm when hospital staff canceled it, citing a "duty to protect her sacred fertility" — a real consequence of these laws already in place. If expanded, these same laws could let providers refuse medical marijuana to patients with chronic pain, PTSD, or anxiety, forcing them back toward pharmaceuticals with documented overdose risks or no treatment at all.
The tension is stark: states like Massachusetts and Missouri are grappling with how to make cannabis markets function and fair, while other states are legislating new ways to restrict patient access to legal cannabis through religious exemptions. Neither approach addresses the root problem — that cannabis remains federally illegal despite state legalization, a contradiction that keeps the industry financially isolated, operationally expensive, and vulnerable to predatory actors. Until federal policy shifts, the cannabis economy will remain a patchwork of state experiments: some trying to stabilize markets and protect social equity, others creating new pathways to deny care.
Researchers at the British Journal of Pharmacology have published findings suggesting that two non-intoxicating cannabis compounds—CBD and cannabigerol (CBG)—may help reverse metabolic dysfunction-associated steatotic liver disease (MASLD), the world's most common chronic liver disorder affecting roughly one-third of the global adult population. 🚀 THIS IS COOL The study identified a novel mechanism: CBD and CBG increase phosphocreatine levels in liver cells, creating energy reserves that help the organ function under the metabolic stress of a high-fat diet, while simultaneously restoring cathepsin enzymes that break down and eliminate harmful fats like triglycerides and ceramides. Study author Dr. Joseph Tam described the effect as "dual metabolic remodeling" that improves hepatic energy and lysosomal function—essentially giving liver cells both the fuel and the cellular cleanup crew they need to recover. CBG showed particular promise for reducing body fat mass and improving insulin sensitivity more effectively than CBD, while both compounds normalized blood sugar levels and reduced harmful cholesterol.
The timing of this research arrives as MASLD affects an estimated one-third of adults globally, yet pharmaceutical treatment options remain limited. Current therapies for metabolic liver disease are sparse, making these findings significant for millions of patients—particularly those with obesity, high blood pressure, or insulin resistance, all conditions closely linked to MASLD progression. The research suggests that CBD and CBG facilitate what researchers call "metabolic remodeling," a recalibration of how the liver processes energy and waste that goes beyond what existing drugs can accomplish.
Meanwhile, 💰 MONEY MOVES Medicare is reportedly preparing to launch a pilot program as early as April 2026 that would provide beneficiaries with up to $500 annually to purchase CBD products—a move that signals a significant shift in how the federal government views cannabis-derived therapeutics for chronic conditions. The proposal frames CBD access as a strategy to address chronic pain, sleep disorders, and anxiety while potentially reducing reliance on opioids and benzodiazepines, two drug classes that carry well-documented addiction and overdose risks. If the program launches, it would represent the largest federal endorsement of CBD as a therapeutic agent to date.
The dual momentum—rigorous peer-reviewed science combined with Medicare program expansion—reflects a broader recalibration in how medical institutions view cannabis compounds. 🤔 THINK ABOUT IT The pharmaceutical industry has spent decades developing synthetic liver treatments with mixed results and significant side effects, yet a plant compound with zero recorded overdose deaths in human history is only now entering federal healthcare programs despite decades of preliminary evidence. The cognitive dissonance is worth noting: these same regulatory bodies have long approved and reimbursed opioids, which kill over 16,000 Americans annually, while keeping cannabis compounds in Schedule I—the federal classification reserved for drugs with "no accepted medical use."
The liver disease findings are particularly striking because they address a condition that has grown exponentially as obesity and metabolic syndrome have spread globally. Unlike pharmaceutical interventions that often work by suppressing symptoms, CBD and CBG appear to work by restoring the liver's native capacity to process energy and eliminate waste—a fundamentally different therapeutic approach that could reshape treatment protocols if clinical trials continue to validate the research. The next phase will be observing whether Medicare's expanded access initiative generates enough real-world data to influence broader healthcare policy and whether other insurers follow suit.
Texas regulators have finalized a sweeping ban on smokable THC products effective March 31, 2026, closing a legal loophole that has allowed hemp-derived cannabis to flourish across the state for the past several years. The Texas Department of State Health Services approved the permanent rules following a public comment period that ended January 26, prohibiting any smokable forms of THC—including THCA, the precursor compound that converts to psychoactive THC when heated. The ban explicitly permits edibles and infused drinks, meaning consumers can still access THC through other delivery methods, but the days of legally purchasing smokable hemp flower at thousands of retail locations across Texas are numbered. 💰 MONEY MOVES The regulatory shift will dramatically reshape the state's cannabis economy: annual retail licensing fees will jump from $150 to $5,000 per location, while manufacturers face increases from $250 to $10,000 per facility—reductions from initial proposals but still a significant financial barrier for smaller operators.
The action traces directly to an executive order issued by Governor Greg Abbott on September 10, 2025, which directed the Department of State Health Services to ban smokable THC products altogether. Abbott's order came after a legislative push in the Texas House and Senate to eliminate THC products outright, and notably, Abbott vetoed Senate Bill 3—legislation backed by Lieutenant Governor Dan Patrick that would have gone even further. The regulatory decision specifically rejected calls from public commenters to exclude THCA from the smokable ban or to narrow the definition of total THC, meaning the state is taking a hard line on a compound that previously allowed retailers and manufacturers to operate in a gray area between federal hemp legality and state marijuana prohibition.
Poison" Rhetoric Meets Campaign Finance Reality
Patrick's aggressive anti-THC stance uses public health language to justify prohibition, but the comparison to legal, documented-lethal substances raises a straightforward question: if the concern is genuinely about protecting public health, why does Texas regulate one zero-death product far more strictly than two substances that collectively kill over 100,000 Americans annually? Campaign finance records and voting patterns show consistent support for policies that protect pharmaceutical and alcohol industry interests while restricting cannabis access.
🎭 Lt. Governor Dan Patrick
🗣️ Says:
“Patrick publicly called THC products "poison" and held press conferences accusing companies of marketing to youth”
👁️ Does:
Patrick backs legislation to ban hemp-derived THC while Texas lawmakers have historically received substantial contributions from the alcohol and pharmaceutical industries—sectors whose products kill tens of thousands of Americans annually
🎤 MIC DROPAlcohol kills approximately 95,000 Americans per year; prescription opioids kill 16,000+; cannabis has zero recorded overdose deaths in human history—yet cannabis remains the target of the "poison" label.
The impact on Texas consumers and retailers will be immediate and severe. Thousands of stores currently licensed to sell hemp products statewide will lose smokable inventory overnight—a sudden market contraction affecting retailers, manufacturers, and consumers who have relied on legally available hemp flower for roughly three years. For Texas veterans in particular, the ban represents reduced access to a product many have used for PTSD, chronic pain, and anxiety management, conditions for which cannabis has shown therapeutic efficacy in peer-reviewed studies. The state's edibles and infused drink market will likely see a surge in demand as consumers shift to non-smokable alternatives, but availability and pricing remain uncertain as the market adjusts to new regulatory caps and fee structures.
🤔 THINK ABOUT IT The smokable ban preserves edible access while eliminating inhalable THC—a regulatory distinction that seems medically arbitrary given that both deliver the same compound at similar bioavailability rates, yet one remains legal and the other becomes contraband in 17 days. If the real concern were THC consumption itself, both would be banned equally. If the concern were youth access, edibles present equal or greater appeal to minors and require no special equipment. The regulatory choice to ban smokables specifically suggests the real target may be market control rather than public health—closing off a product category that has proven popular, accessible, and profitable for small retailers across Texas.
